Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)
Phase 3
Completed
- Conditions
- Pneumonia
- Registration Number
- NCT00074906
- Lead Sponsor
- Takeda
- Brief Summary
Study to demonstrate that administration of Venticute increases survival of patients with pneumonia or aspiration of gastric contents leading to intubation, mechanical ventilation, and severe oxygenation impairment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1200
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Survival on day 28 28 days
- Secondary Outcome Measures
Name Time Method How long the lung and the patient (overall) are recovering 28 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Venticute target in pneumonia and aspiration-induced respiratory failure?
How does Venticute compare to standard-of-care treatments for severe pneumonia requiring mechanical ventilation?
Are there specific biomarkers that predict patient response to Venticute in NCT00074906 trial?
What are the known adverse events associated with Venticute in phase 3 trials for pneumonia?
What related compounds or combination therapies are being explored for aspiration pneumonia by Takeda?
Trial Locations
- Locations (1)
Altana Pharma/Nycomed
🇬🇧West Lothian, United Kingdom
Altana Pharma/Nycomed🇬🇧West Lothian, United Kingdom